Aetna backs Gilead's hepatitis C treatment and gets discount

January 16, 2015 7:37 PM

19 0

(Reuters) - Aetna Inc, the third-largest U.S. health insurer, said it has negotiated a discount with Gilead Sciences Inc for its hepatitis C treatment and will offer it as the preferred choice to its nearly 20 million commercial customers.

Aetna, which posted an updated coverage policy on its website on Friday, said in a statement that it believes its price is "competitive with other recently announced agreements for this class of therapy."

Also read: FDA Approves First Nonopioid Treatment for Opioid Withdrawal Symptoms

Read more

To category page